Anika Therapeutics
ANIK
115 hedge funds and large institutions have $242M invested in Anika Therapeutics in 2023 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 29 increasing their positions, 45 reducing their positions, and 28 closing their positions.
0.05% less ownership
Funds ownership: 88.76% → 88.7% (-0.05%)
7% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 28
2% less funds holding
Funds holding: 117 → 115 (-2)
29% less capital invested
Capital invested by funds: $340M → $242M (-$98.1M)
36% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 45
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
67% less call options, than puts
Call options by funds: $17K | Put options by funds: $52K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$9.2M |
| 2 |
TI
Trigran Investments
Northbrook,
Illinois
|
+$8.51M |
| 3 |
CP
Caligan Partners
New York
|
+$7.49M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$4.52M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$2.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$21.6M |
| 2 |
State Street
Boston,
Massachusetts
|
-$9.46M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4M |
| 4 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$2.82M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$2.44M |
ANIK Hedge Fund Activity: Q3 2023 in Review
115 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q3 2023, worth a combined $242M — down 29% from $340M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of ANIK and 26 opened new positions — a net loss of 2 holders — while 45 trimmed existing stakes and 29 added.
The largest buyer was Millennium Management, adding an estimated $9.2M. The largest seller was BlackRock, cutting an estimated $21.6M.
- 115 institutional investors held Anika Therapeutics (ANIK) as of Q3 2023, down from 117 in Q2 2023.
- Funds reported $242M of Anika Therapeutics stock for Q3 2023, down 29% quarter-over-quarter.
- 26 funds opened new Anika Therapeutics positions in Q3 2023 and 28 closed out, a net change of -2 holders.
- The largest Anika Therapeutics buyer in Q3 2023 was Millennium Management, an estimated $9.2M added.
- The largest Anika Therapeutics seller in Q3 2023 was BlackRock, an estimated $21.6M sold.
Based on aggregated 13F filings for Q3 2023.